Stockscreener 앱 받기
3.0403
6.31%
-0.1297
전일 마감가:
$3.17
열려 있는:
$3
하루 거래량:
17,618
Relative Volume:
0.09
시가총액:
$3.83M
수익:
-
순이익/손실:
$-4.74M
주가수익비율:
-4.0537
EPS:
-0.75
순현금흐름:
$-3.46M
1주 성능:
-6.31%
1개월 성능:
-0.67%
6개월 성능:
-26.72%
1년 성능:
-63.60%
1일 변동 폭
$2.95
$3.171
1주일 범위
$2.92
$3.70
52주 변동 폭
$2.21
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
명칭
Lipella Pharmaceuticals Inc
전화
412-901-0315
주소
400 N LEXINGTON ST, PITTSBURGH
LIPO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.97 | 3.83M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.95 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
708.54 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
661.00 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.09 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.17 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lipella Pharmaceuticals Inc 주식(LIPO)의 최신 뉴스
Lipella Pharmaceuticals Inc. Announces Second Closing of Offering 2024 - Defense World
SABBY MANAGEMENT, LLC Acquires 60,325 Shares in Lipella Pharmace - GuruFocus.com
Lipella Pharmaceuticals Inc. Enters into Agreement with Spartan Capital Securities, LLC and Closes Initial OfferingThe pharmaceutical company Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) recently disclosed in an 8-K filing with the U.S. Securities and - Defense World
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions - GlobeNewswire Inc.
Lipella Pharmaceuticals Cancels Special Meeting Due to Lack of Quorum - Defense World
Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Lipella Pharmaceuticals Enters into Placement Agent and Consulting Agreements - Defense World
Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com
Lipella Pharmaceuticals reschedules special meeting - Investing.com
Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan
Critical Review: Lipella Pharmaceuticals (LIPO) & Its Peers - Defense World
Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
Lipella Pharmaceuticals Inc (LIPO) Quarterly 10-Q Report - Quartzy
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipella issued patent by USPTO for liposomal drug delivery platform - TipRanks
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform - The Manila Times
Lipella Pharmaceuticals Secures Extended Market Exclusivity - GlobeNewswire
Lipella Pharma Secures Key Patent for Liposomal Platform, Extends Drug Pipeline Protection to 2035 | LIPO Stock News - StockTitan
China chip index nears 3-year high as TSMC order fuels self-reliance bets - Investing.com
Cathay general bancorp vice chairman sells $2.11 million in stock - Investing.com
Contrasting Wellness Center USA (OTCMKTS:WCUI) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Lipella Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com Australia
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - citybiz
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals announces 1-for-8 reverse stock split By Investing.com - Investing.com UK
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
0.45%
자본화:
|
볼륨(24시간):